Triazole-based compound as a candidate to develop novel medicines to treat toxoplasmosis.

Authors :: Dzitko K
Paneth A
Plech T
Pawełczyk J
Węglińska L
Paneth P
Source :: Antimicrobial agents and chemotherapy [Antimicrob Agents Chemother] 2014 Dec; Vol. 58 (12), pp. 7583-5. Date of Electronic Publication: 2014 Oct 06.
Publication Year :: 2014
Abstract: This article reports anti-Toxoplasma gondii activity of 3-(thiophen-2-yl)-1,2,4-triazole-5-thione. The compound displayed significant and reproducible antiparasitic effects at nontoxic concentrations for the host cells, with an experimentally determined 50% inhibitory concentration (IC50) at least 30 times better than that of the known chemotherapeutic agent sulfadiazine. Purine nucleoside phosphorylase was defined as the probable target for anti-Toxoplasma activity of the tested compound. These results provide the foundation for future work to develop a new class of medicines to better treat toxoplasmosis.<br /> (Copyright © 2014, American Society for Microbiology. All Rights Reserved.)

Full Text Access

Tools